Terms: = Ovarian cancer AND KLF4, EZF, 9314, ENSG00000136826, GKLF, O43474 AND Prognosis
4 results:
1. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
[TBL] [Abstract] [Full Text] [Related]
2. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/klf4/AKT1 axis in ovarian cancer.
Zhang L; Zhou Q; Qiu Q; Hou L; Wu M; Li J; Li X; Lu B; Cheng X; Liu P; Lu W; Lu Y
Mol Cancer; 2019 Oct; 18(1):144. PubMed ID: 31623606
[TBL] [Abstract] [Full Text] [Related]
3. LINC01210 accelerates proliferation, invasion and migration in ovarian cancer through epigenetically downregulating klf4.
Zhang C; Liu J; Zhang Y; Luo C; Zhu T; Zhang R; Yao R
Biomed Pharmacother; 2019 Nov; 119():109431. PubMed ID: 31514068
[TBL] [Abstract] [Full Text] [Related]
4. KCNN4 and S100A14 act as predictors of recurrence in optimally debulked patients with serous ovarian cancer.
Zhao H; Guo E; Hu T; Sun Q; Wu J; Lin X; Luo D; Sun C; Wang C; Zhou B; Li N; Xia M; Lu H; Meng L; Xu X; Hu J; Ma D; Chen G; Zhu T
Oncotarget; 2016 Jul; 7(28):43924-43938. PubMed ID: 27270322
[TBL] [Abstract] [Full Text] [Related]
